Diaceutics PLC Investor presentation
May 28 2019 - 1:02AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
28 May 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Investor presentation
Diaceutics PLC (AIM: DXRX), the data analytics and
implementation services company which services the global
pharmaceutical industry, announces it will hold an investor
presentation on Monday, 17 June 2019.
The investor event will take place at the Copper Bar, Balls
Brothers, 6 Adams Court, London EC2N 1DX at 4.30pm for a 4.45pm
start. This will be followed by drinks and canapés, and a chance to
network with the management.
Peter Keeling, CEO, will provide an introduction to the Company
and an overview of the business.
If you would like to register to attend the investor briefing or
require further information, please contact Walbrook PR on 020 7933
8780 or email diaceutics@walbrookpr.com.
No new material information will be disclosed at the event.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive Via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics has established a suite of data-driven products and
implementation services powered by the data held in its proprietary
database. Its products and services are focused on optimising its
clients' strategies for the development and launch of precision
medicines and specifically, the diagnostic testing required to
guide selection of such medicines. The Company provides services to
20 of the 30 largest global pharmaceutical companies.
Since its inception in 2005, Diaceutics has focused on the
diagnostic testing market, collating large amounts of laboratory,
patient (on an anonymised and aggregated basis), claims and payor
data which it uses to deliver diagnostic testing strategies to its
clients. The Group has amassed a set of more than 115 million
patient records from over 2,500 laboratories across 35 countries
around the world. As part of this data collection, it has
accumulated a proprietary database of laboratory capabilities
across the industry.
About Precision Medicines
Precision medicines (or therapies) are a class of drug tailored
to individual patient groups dependent on molecular or genetic
factors of the individual. Today, they are used for treatment in
oncology as well as other disease areas such as multiple sclerosis
and rheumatoid arthritis. The increasing use of precision medicines
results from the fact that some drugs have demonstrated significant
positive clinical results in some patients but have been shown to
be less effective or less safe across the entire patient
population.
Given the specific nature of precision therapeutics, the
successful roll-out of these medicines by a pharmaceutical company
is increasingly reliant on having effective and wide-spread testing
available for doctors and patients from launch.
Diaceutics' products and services
Diaceutics' products and services are predominantly focused on
diagnostic tests carried out in laboratories which are used
alongside a precision medicine to identify which patients will
benefit most from that drug. From the pharmaceutical company's
perspective, it is essential that from launch, it has optimised the
practical process for testing of potential patients by labs to
ensure the highest levels of drug sales from the outset. Failure to
have effective testing can significantly reduce the adoption of the
relevant drug. Despite the increasing importance of effective
diagnostic testing, the testing market itself remains highly
fragmented and the pharmaceutical industry has varied insight into
it. The Directors believe that the addressable market for their
specific services today is approximately US$0.5 billion. With
expected market growth in the number of test dependent therapies
alongside increased investment by pharma to remove testing hurdles
to seamless treatment, Diaceutics forecast the overall market will
increase to US$2.5 billion by 2023.
The Group's services are split into the following four discrete,
sequential modules:
-- Landscape - initial views on the testing environment for
pharmaceutical companies that often have little insight into the
actual data required to make decisions in advance of a launch.
-- Planning - advising on steps to ensure rapid and effective
test adoption, including advice on how tests should be developed,
who they should be developed with and how should they be optimally
communicated to physicians and patients.
-- Implementation - identifying and solving issues with leading
laboratories relating to the adoption and efficacy of testing.
-- Tracking - ongoing post launch analysis to understand how
testing is promoting or restricting access to precision
therapy.
The Directors believe that these services benefit pharma clients
with improved return on investment, reduced time to peak market
penetration and greater revenue potential in relation to their
precision therapeutic development programmes. The Group's products
also improve testing outcomes for patients, enabling better access
to the right drug at the right time. During 2018, the Group, which
is headquartered in Belfast, Northern Ireland and has offices in
Dundalk, Co. Louth, New Jersey in the US and in Singapore, had an
average of 65 full time employees in 17 different countries. The
Group achieved compound annual revenue growth in sales of over 50
per cent from 2016 to 2018.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAQZLFLKEFZBBZ
(END) Dow Jones Newswires
May 28, 2019 02:02 ET (06:02 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024